MPI-0441138 (EP128265) is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor of specific protein kinases that play a critical role in cancer cell proliferation and survival. By targeting these kinases, it aims to disrupt signaling pathways that are often dysregulated in various types of cancers, thereby inhibiting tumor growth and progression. This compound is being studied in preclinical and clinical settings to evaluate its efficacy and safety as a targeted cancer therapy. Its application could offer a more precise treatment option for patients with cancers that are resistant to conventional therapies. Additionally, research is ongoing to explore its potential in combination with other anticancer agents to enhance therapeutic outcomes.